Importantly, mice treated with S100A8 had significantly less S100A8+ and S100A9+ myeloid cells in the neoplastic masses (S100A8: 2 cells per field of view, p < 0.0001; S100A9: 4 cells per field of view, p < 0.05) (Figures 5A–F), suggesting that S100A8 reduced MDSC accumulation in lungs with cancers. Here, S100A9 is linked to cancer.